The spectrum of mutations in genes associated with resistance to rifampicin, isoniazid, and fluoroquinolones in the clinical strains of M. tuberculosis reflects the transmissibility of mutant clones
- 作者: Ergeshov A.1, Andreevskaya S.N.1, Larionova E.E.1, Smirnova T.G.1, Chernousova L.N.1
-
隶属关系:
- Central Tuberculosis Research Institute
- 期: 卷 51, 编号 4 (2017)
- 页面: 526-532
- 栏目: Genomics. Transcriptomics
- URL: https://journal-vniispk.ru/0026-8933/article/view/163131
- DOI: https://doi.org/10.1134/S0026893317030049
- ID: 163131
如何引用文章
详细
To study the transmissibility of drug resistant mutant clones, M. tuberculosis samples were isolated from the patients of the clinical department and the polyclinic of the Central TB Research Institute (n = 1455) for 2011–2014. A number of clones were phenotypically resistant to rifampicin (n = 829), isoniazid (n = 968), and fluoroquinolones (n = 220). We have detected 21 resistance-associated variants in eight codons of rpoB, six variants in three codons of katG, three variants in two positions of inhA, four variants in four positions of ahpC, and nine variants in five codons of gyrA, which were represented in the analyzed samples with varied frequencies. Most common mutations were rpoB 531 Ser→Leu (77.93%), katG 315 (Ser→Thr) (94.11%), and gyrA 94 (Asp→Gly) (45.45%). We found that the mutations at position 15 of inhA (C→T) (frequency of 25.72%) are commonly associated with katG 315 (Ser→Thr). This association of two DNA variants may arise due to the double selection by coexposure of M. tuberculosis to isoniazid and ethionamide. The high transmissibility of mutated strains was observed, which may be explained by the minimal influence of the resistance determinants on strain viability. The high transmissibility of resistant variants may also explain the large populational prevalence of drug-resistant TB strains.
作者简介
A. Ergeshov
Central Tuberculosis Research Institute
Email: andsofia@mail.ru
俄罗斯联邦, Moscow, 107564
S. Andreevskaya
Central Tuberculosis Research Institute
编辑信件的主要联系方式.
Email: andsofia@mail.ru
俄罗斯联邦, Moscow, 107564
E. Larionova
Central Tuberculosis Research Institute
Email: andsofia@mail.ru
俄罗斯联邦, Moscow, 107564
T. Smirnova
Central Tuberculosis Research Institute
Email: andsofia@mail.ru
俄罗斯联邦, Moscow, 107564
L. Chernousova
Central Tuberculosis Research Institute
Email: andsofia@mail.ru
俄罗斯联邦, Moscow, 107564
补充文件
